

USSN: 10/809,176
Attorney Docket: I-2003.002 US
Response to Non-Compliant Amendment of December 1, 2006

Amendments to the Claims:

1. **(Currently Amended):** A classic infectious bursal disease virus (IBDV) mutant that expresses a VP2 protein that binds with monoclonal antibody (moab) B69, **characterised in that wherein** the VP2 protein also binds with moab 67, secreted by hybridoma cell lines HB-9437 and HB-11122, deposited at the ATCC, Rockville, USA, respectively.
2. **(Currently Amended):** **[[A]] The** classic IBDV mutant according to claim 1, **characterised in that wherein** the VP2 protein binds with moab B69, moab 67 and moab R63, secreted by hybridoma cell line HB-9490, deposited at the ATCC, Rockville, USA.
3. **(Currently Amended):** **[[A]] The** classic IBDV mutant according to claim 1, **characterised in that wherein** the mutant comprises one or more mutations in a classic VP2 coding region, such that the coding region comprises,
 - (i) a codon for the amino acid at position 222 encoding **an amino acid selected from the group consisting of** serine **[[or]] and** threonine, and
 - (ii) a nucleotide sequence encoding an amino acid sequence **shown in any of the SEQ ID. No. 1-5 selected from the group consisting of SEQ ID. No. 1, SEQ ID. No. 2, SEQ ID. No. 3, SEQ ID. No. 4 and SEQ ID. No. 5** at positions 318-323.
4. **(Currently Amended):** A classic IBDV mutant according to claim 3, **characterised in that wherein** the coding region comprises a codon for the amino acid at position 330 encoding **an amino acid selected from the group consisting of** arginine **[[or]] and** serine.

USSN: 10/809,176

Attorney Docket: I-2003.002 US

Response to Non-Compliant Amendment of December 1, 2006

5. (Currently Amended): [[A]] The classic IBDV mutant according to ~~claims 1-4~~, characterised in that claim 1, wherein the mutant comprises one or more mutations in a VP2 coding region of IBDV strain D78.
6. (Currently Amended): [[A]] The classic IBDV mutant according to ~~claims 1-5~~, characterised in that claim 1, wherein the mutant comprises a genomic segment A of a classic IBDV, preferably of IBDV strain D78.
7. (Currently Amended): A vaccine for use in the protection of poultry against disease caused by IBDV infection, characterised in that wherein the vaccine comprises a classic IBDV mutant according to ~~claims 1-6~~ claim 1, together with a pharmaceutical acceptable carrier or diluent.
8. (Currently Amended): [[A]] The vaccine according to claim 7, characterised in wherein the classic IBDV mutant is in a live form.
9. (Currently Amended): [[A]] The vaccine according to claim 7 or 8, characterised in that, wherein the vaccine further comprises one or more vaccine components of other pathogens infectious to poultry.
10. (Currently Amended): [[A]] The vaccine according to ~~claims 7-9~~, characterised in that claim 7, wherein the vaccine comprises an adjuvant.
11. (Currently Amended): A method for the preparation of a classic IBDV mutant according to ~~claims 1-6~~ claim 1, characterised in that the classic IBDV mutant is propagated in a cell culture and subsequently harvested from the cell culture.

USSN: 10/809,176
Attorney Docket: I-2003.002 US
Response to Non-Compliant Amendment of December 1, 2006

12. (Currently Amended): A method for the preparation of a vaccine ~~according to claims 7-10, characterised in that wherein~~ a classic IBDV mutant according to ~~claims 1-6~~ claim 1 is mixed with a pharmaceutical acceptable carrier or a diluent.

13. (Original): A method for the preparation of a classic infectious bursal disease virus (IBDV) mutant that expresses a VP2 protein that binds with monoclonal antibody (moab) B69 and moab 67, secreted by hybridoma cell lines HB-9437, and HB-11122, deposited at the ATCC, Rockville, USA, respectively, characterised in that one or more mutations are introduced in a VP2 coding region of a classic IBDV strain, such that ,
(i) a codon for the amino acid at position 222 encodes serine or threonine, and
(ii) a nucleotide sequence encoding an amino acid sequence for positions 318-323 encodes an amino acid sequence shown in any of the SEQ ID No. 1-5.

14. (Currently Amended): [[A]] The method according to claim 13, characterised in that the mutation is introduced in the codon for the amino acid at position 222 in a VP2 coding region of a classic IBDV strain that comprises a nucleotide sequence encoding the amino acid sequence shown in SEQ ID No. 1.

15. (Currently Amended): [[A]] The method according to claim 13 ~~or 14~~, characterised in that the VP2 protein also binds with moab R63, secreted by hybridoma cell line HB-9490, deposited at the ATCC, Rockville, USA.

16. (Currently Amended): [[A]] The method according to ~~claims 13-15~~ claim 13, characterised in that the VP2 coding region comprises a codon for the amino acid at position 330 encoding arginine or serine.

USSN: 10/809,176

Attorney Docket: I-2003.002 US

Response to Non-Compliant Amendment of December 1, 2006

17. (Currently Amended): [[A]] The method according to ~~claims 13-17~~ claim 13, characterised in that the one or more mutations are introduced in a VP2 coding region of IBDV strain D78.

18. (Currently Amended): [[A]] The method according to ~~claims 13-17~~ claim 13, characterised in that the one or more mutations are introduced in a genomic segment A of a classic IBDV, preferably of IBDV strain D78.

19. (Currently Amended): A method for the preparation of a vaccine for use in the protection of poultry against disease caused by IBDV infection, characterised in that a classic IBDV mutant prepared according to a method described in ~~claims 13-18~~ claim 13 is mixed with a pharmaceutical acceptable carrier or a diluent.